MARKET

SPHS

SPHS

Sophiris Bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7199
-0.0004
-0.06%
Opening 12:06 09/18 EDT
OPEN
0.7286
PREV CLOSE
0.7203
HIGH
0.7380
LOW
0.7127
VOLUME
35.76K
TURNOVER
--
52 WEEK HIGH
2.950
52 WEEK LOW
0.7100
MARKET CAP
24.17M
P/E (TTM)
-11.6300
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SPHS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

SPHS News

  • Sophiris Bio (SPHS) Investor Presentation - Slideshow
  • Seeking Alpha - Article.1d ago
  • Sophiris Bio Announces Completion of $4.0 Million Registered Direct Offering
  • PR Newswire.08/30 13:00
  • Sophiris Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference
  • PR Newswire.08/30 13:00
  • SPHS: Awaiting Feedback from FDA on Phase 3 Plan for Topsalysin in Prostate Cancer
  • Zacks Small Cap Research.08/27 16:05

More

Industry

Pharmaceuticals
-0.02%
Pharmaceuticals & Medical Research
-0.23%

Hot Stocks

Name
Price
%Change

About SPHS

Sophiris Bio Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing products for the treatment of urological diseases. The Company is developing topsalysin (PRX302) as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia (BPH) commonly referred to as an enlarged prostate and as a treatment for localized low to intermediate risk prostate cancer. Topsalysin, a genetically modified recombinant protein, is delivered through ultrasound-guided injection directly into the prostate. This membrane-disrupting protein is selectively activated by enzymatically active prostate specific antigen (PSA), which is only present in the prostate, leading to localized cell death and tissue disruption without damage to neighboring tissue and nerves. This method of administration limits the circulation of the drug in the body. The Company has completed Phase III clinical trials of topsalysin.
More

Webull offers Sophiris Bio Inc (SPHS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.